Table 2.
List of differentially expressed proteins of relapsing versus not-relapsing plasma collected from patients of the 'explorative' cohort affected by Hodgkin lymphoma.
| Spot nr. a) | MW(Da)/pI | Database | Accession | Protein annotation | Score | Matches | Seq.b) | Seq. cov. % c) | Fold △ | p-value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (a) up-regulated spots (nr=9) in 'not relapsing, NR' patients | |||||||||||
| 273 | 44305/5.37 | NCBInr | 1::gi|196049621 | Chain A, Crystal Structure Of Alpha-1-Antitrypsin, Crystal Form A | 1397 | 252 | 30 | 50 | -6.79 | 4.29E-04 | |
| 272 | 44305/5.37 | NCBInr | 1::gi|196049621 | Chain A, Crystal Structure Of Alpha-1-Antitrypsin, Crystal Form A | 2011 | 337 | 29 | 49 | -6.14 | 2.68E-04 | |
| 266 | 45344/5.28 | NCBInr | 1::gi|71773110 | Apolipoprotein A-IV precursor | 873 | 65 | 35 | 62 | -5.83 | 1.77E-03 | |
| 44305/5.37 | NCBInr | 1::gi|196049621 | Chain A, Crystal Structure Of Alpha-1-Antitrypsin, Crystal Form A | 594 | 59 | 23 | 40 | ||||
| 264 | 44305/5.37 | NCBInr | 1::gi|196049621 | Chain A, Crystal Structure Of Alpha-1-Antitrypsin, Crystal Form A | 1416 | 152 | 28 | 54 | -4.85 | 2.07E-04 | |
| 267 | 103521/6.51 | SwissProt | 2::ITIH4_HUMAN | Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 | 505 | 31 | 17 | 14 | -4.76 | 3.09E-04 | |
| 45371/5.28 | SwissProt | 2::APOA4_HUMAN | Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 | 462 | 40 | 27 | 48 | ||||
| 255 | 44305/5.37 | NCBInr | 1::gi|196049621 | Chain A, Crystal Structure Of Alpha-1-Antitrypsin, Crystal Form A | 536 | 63 | 24 | 40 | -3.12 | 2.52E-03 | |
| 258 | 46823/5.54 | NCBInr | 1::gi|223170 | Fibrinogen gamma | 430 | 34 | 16 | 29 | -3.02 | 3.50E-03 | |
| 103521/6.51 | SwissProt | 2::ITIH4_HUMAN | Inter-alpha-trypsin inhibitor heavy chain | 358 | 20 | 15 | 14 | ||||
| 259 | 103521/6.51 | SwissProt | 2::ITIH4_HUMAN | Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 | 486 | 34 | 18 | 15 | -2.94 | 6.71E-05 | |
| 53025/6.32 | SwissProt | 2::ANT3_HUMAN | Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 | 375 | 30 | 19 | 27 | ||||
| 233 | 55069/5.55 | SwissProt | 2::VTNC_HUMAN | Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 | 603 | 33 | 14 | 20 | -2.06 | 9.99E-03 | |
| (b) up-regulated spots (nr=11) in 'relapsing, R' patients | |||||||||||
| 230 | 95656/5.70 | SwissProt | 2::FIBA_HUMAN | Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 | 5271 | 374 | 53 | 39 | 3.41 | 1.44E-05 | |
| 234 | 95656/5.70 | SwissProt | 2::FIBA_HUMAN | Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 | 5862 | 403 | 51 | 37 | 2.5 | 1.09E-03 | |
| 196 | 95656/5.70 | SwissProt | 2::FIBA_HUMAN | Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 | 3643 | 250 | 41 | 34 | 2.41 | 2.08E-04 | |
| 239 | 61305/7.31 | NCBInr | 1::gi|237823914 | Chain A, Crystal Structure Of Human Fibrinogen | 13094 | 731 | 43 | 55 | 2.23 | 2.84E-03 | |
| 300 | 52908/7.14 | NCBInr | 1::gi|237823915 | Chain B, Crystal Structure Of Human Fibrinogen | 14481 | 655 | 34 | 62 | 2.16 | 7.70E-03 | |
| 291 | 52908/7.14 | NCBInr | 1::gi|237823915 | Chain B, Crystal Structure Of Human Fibrinogen | 20618 | 826 | 40 | 80 | 2.08 | 1.89E-03 | |
| 296 | 52908/7.14 | NCBInr | 1::gi|237823915 | Chain B, Crystal Structure Of Human Fibrinogen | 15220 | 755 | 38 | 67 | 2.05 | 6.22E-03 | |
| 78 | 61305/7.31 | NCBInr | 1::gi|237823914 | Chain A, Crystal Structure Of Human Fibrinogen | 509 | 25 | 13 | 32 | 2.01 | 3.17E-03 | |
| 188569/6.02 | SwissProt | 2::CO3_HUMAN | Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 | 402 | 38 | 22 | 11 | ||||
| 77 | 188569/6.02 | SwissProt | 2::CO3_HUMAN | Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 | 537 | 33 | 29 | 12 | 1.90 | 3.41E-04 | |
| 46823/5.54 | NCBInr | 1::gi|223170 | Fibrinogen gamma | 534 | 52 | 19 | 33 | ||||
| 98 | 52908/7.14 | NCBInr | 1::gi|237823915 | Chain B, Crystal Structure Of Human Fibrinogen | 2461 | 164 | 28 | 51 | 1.82 | 6.01E-03 | |
| 67 | 122983/5.44 | SwissProt | 2::CERU_HUMAN |
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 |
785 | 29 | 21 | 18 | 1.58 | 4.19E-03 | |
a)spot nr., spot numbers refer to Figure 1; b)Seq., sequences; c)Seq. cov. %, percentage of sequence coverage.